

## Annex 2

Drugs covered by SF	Patients' contribution for drug expenses in cases approved for partial subsidy (\$)	Number of applications approved	Sub-total	Number of applications approved	Sub-total	Number of applications approved	Sub-total
		2009-10		2010-11		2011-12	
1 Interferon :	< \$10,000	25		11		12	
	\$10,000 - < \$50,000	7		4		5	
	\$50,000 - < \$100,000	0		1		0	
	>= \$100,000	0		0		0	
			32		16		17
2 Adalimumab :	< \$10,000	0		10		15	
	\$10,000 - < \$50,000	0		4		10	
	\$50,000 - < \$100,000	0		0		3	
	>= \$100,000	0		0		0	
			0		14		28
3 Bortezomib :	< \$10,000	0		8		6	
	\$10,000 - < \$50,000	0		4		6	
	\$50,000 - < \$100,000	0		2		0	
	>= \$100,000	0		1		2	
			0		15		14
4 Cetuximab :	< \$10,000	0		7		3	
	\$10,000 - < \$50,000	1		2		2	
	\$50,000 - < \$100,000	0		0		0	
	>= \$100,000	0		0		0	
			1		9		5
5 Dasatinib :	< \$10,000	0		4		3	
	\$10,000 - < \$50,000	0		1		2	
	\$50,000 - < \$100,000	0		1		2	
	>= \$100,000	0		0		1	
			0		6		8
6 Etanercept :	< \$10,000	17		24		24	
	\$10,000 - < \$50,000	10		13		18	
	\$50,000 - < \$100,000	1		3		5	
	>= \$100,000	0		0		0	
			28		40		47
7 Erlotinib :	< \$10,000	0		0		3	
	\$10,000 - < \$50,000	0		0		4	
	\$50,000 - < \$100,000	0		0		0	
	>= \$100,000	0		0		1	
			0		0		8

Drugs covered by SF	Patients' contribution for drug expenses in cases approved for partial subsidy (\$)	Number of applications approved	Sub-total	Number of applications approved	Sub-total	Number of applications approved	Sub-total
		2009-10		2010-11		2011-12	
8 Gefitinib :	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	0 0 0 0	0	0 0 0 0	0	7 3 3 1	14
9 Infliximab :	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	29 19 1 0	49	29 17 1 0	47	22 6 1 0	29
10 Nilotinib :	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	0 0 0 0	0	12 6 2 2	22	6 7 3 1	17
11 Oxaliplatin :	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	7 4 0 0	11	17 13 0 0	30	18 6 0 0	24
12 Pemetrexed :	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	0 0 0 0	0	1 0 0 0	1	1 1 0 0	2
13 Rituximab : malignant lymphoma	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	20 28 5 0	53	35 28 12 6	81	30 41 17 7	95
14 Temozolomide :	< \$10,000 \$10,000 - < \$50,000 \$50,000 - < \$100,000 ≥ \$100,000	0 0 0 0	0	0 0 0 0	0	1 1 1 1	4

Drugs covered by SF	Patients' contribution for drug expenses in cases approved for partial subsidy (\$)	Number of applications approved	Sub-total	Number of applications approved	Sub-total	Number of applications approved	Sub-total
		2009-10		2010-11		2011-12	
15 <b>Trastuzumab :</b>	< \$10,000	19		63		35	
	\$10,000 - < \$50,000	17		46		64	
	\$50,000 - < \$100,000	10		33		42	
	>= \$100,000	<u>3</u>		<u>36</u>		<u>24</u>	
			49		178		165
16 <b>Imatinib (i.e. Glivec) :</b>	< \$10,000	70		76		76	
	\$10,000 - < \$50,000	45		56		57	
	\$50,000 - < \$100,000	19		16		24	
	>= \$100,000	<u>8</u>		<u>19</u>		<u>9</u>	
			142		167		166
17 <b>Irinotecan (Campto) :</b>	< \$10,000	22		0		0	
	\$10,000 - < \$50,000	2		0		0	
	\$50,000 - < \$100,000	0		0		0	
	>= \$100,000	<u>0</u>		<u>0</u>		<u>0</u>	
			24		0		0
<b>Total</b>	< \$10,000	209		297		262	
	\$10,000 - < \$50,000	133		194		233	
	\$50,000 - < \$100,000	36		71		101	
	>= \$100,000	<u>11</u>		<u>64</u>		<u>47</u>	
			389		626		643